Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
Adult T-cell Leukemia/Lymphoma
DRUG: Valemetostat Tosylate
Overall response rate (ORR) assessed by central evaluation organization, The percentage of participants who were assessed for best overall response, who achieved complete remission (CR), complete remission, unconfirmed (CRu) or partial remission (PR) by central evaluation organization., Through the end of the study (within approximately 5 years)
Overall response rate (ORR) assessed by investigator, The percentage of participants who were assessed for best overall response, who achieved CR, CRu, or PR by investigator., Through the end of the study (within approximately 5 years)|Best response per tumor lesions, Best response in target lesions (nodal or extranodal lesions), peripheral blood lesions, and skin lesions., Through the end of the study (within approximately 5 years)|Complete remission rate (CR rate), The percentage of participants who were assessed for best overall response, who achieved CR or CRu., Through the end of the study (within approximately 5 years)|Tumor control rate (TCR), The percentage of participants who were assessed for best overall response, who achieved CR, CRu, PR or stable disease (SD)., Through the end of the study (within approximately 5 years)|Time to response (TTR), Period from the first day of DS-3201b dose to the first day of CR, CRu, or PR, Through the end of the study (within approximately 5 years)|Duration of response (DOR), Period from first CR, CRu, or PR to residual disease/progressive disease (RD/PD) or death., Through the end of the study (within approximately 5 years)|Progression-free survival (PFS), Period from the first day of DS-3201b dose to the day of RD/PD or death., Through the end of the study (within approximately 5 years)|Overall survival (OS), Period from the first day of DS-3201b dose to death., Through the end of the study (within approximately 5 years)
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).